ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025
Encapsulation of Flucytosine into nanoliposomes for enhanced antifungal activity against Candida glabrata and Candida albicans.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Flucytosine (FC) is currently used as an antifungal drug for the treatment of infectious diseases. However, due to the development of drug resistance, the monotherapy of FC is limited. Recently, nanoliposomes have been studied as promising approaches to overcome microbial resistance. In this study, we encapsulate FC in the nanoliposomes and investigate their physicochemical properties as well as antifungal activities against Candida glabrata and Candida albicans in-vitro. Various liposomal formulations of FC were prepared based on the modified freeze-drying of a monophase solution method. The nanoliposomes were characterized in terms of size, zeta potential, transmission electron microscopy image, encapsulation efficiency, stability, release, crystallography, and cytotoxicity. Also, the minimum inhibitory concentration and minimum fungicidal concentration were determined against C. glabrata and C. albicans. The size and zeta potential of the selected nanoliposomes were 147.33 ± 23.25 nm and - 31.20 ± 9.05 mV, respectively. Encapsulation efficiency was 46.7 ± 7.5% in the selected formulation. TEM results revealed that the nanoliposomes were nano-sized and spherical. Release results indicated that the nanoliposomes had a slow-release rate of FC. The fungal eradication of nanoliposomal FC was at least two times higher than that of the free drug for C. glabrata and C. albicans. Cytotoxicity studies demonstrated no significant toxicity at effective concentrations of nanoliposomal FC. The stability of the nano-formulation was temperature-dependent, and the refrigerator showed the best condition for long-term storage. Nanoliposomal FC prepared using the modified freeze-drying of a monophase solution method seems promising and may be used to overcome the fungal resistance relative to FC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.